Citations

Clear

116 citation(s) found for "Davis, Mark".

Climate change, human migration, and skin disease: is there a link?
Sugiharto, Audi , Coates, Sarah J. , Lucero‐Prisno, Don Eliseo , Davis, Mark Denis D., Andersen, Louise K. , Sugiharto, Audi , Coates, Sarah J , Lucero-Prisno, Don Eliseo , Andersen, Louise K , Dayrit, Johannes F.

Mayo Clinic

International Journal of Dermatology | May 10, 2021 | Volume: 61 | Issue: 2 | Pages: 127-138

10.1111/ijd.15543 | PMID 33971021 Get It

Abstract Climate change, exemplified by higher average global temperatures resulting in more frequent extreme weather events, has the potential to significantly impact human migration patterns and health. The consequences of environmental catastrophes further destabilize regions with pre‐existing states of conflict due to social, political, and/or economic unrest. Migrants may carry diseases from their place of origin to their destinations and once there may be susceptible to diseases in which they had not been previously exposed to. Skin diseases are among the most commonly observed health conditions observed in migrant populations. To improve awareness among dermatologists of the burden of skin diseases among migrants, the group searched the English language scientific literature to identify articles linking climate change, migration, and skin disease. Skin diseases associated with human migration fall into three major categories: (i) communicable diseases, (ii) noncommunicable diseases, and (iii) environmentally mediated diseases. Adopting comprehensive global strategies to improve the health of migrants requires urgent attention.
Intertriginous ulcers attributable to multidrug‐resistant Candida species
Brough, Kevin, Dykstra, Jordan, Comfere, Nneka I. , Davis, Mark D.P. , Brough, Kevin R

Mayo Clinic

International Journal of Dermatology | March 24, 2021 | Volume: 60 | Issue: 9 | Pages: No page available

10.1111/ijd.15521 | PMID 33760248 Get It

Topical Amitriptyline-Ketamine for Treatment of Rectal, Genital, and Perineal Pain and Discomfort
Davis, Mark D. P., Davis, Mark D.P.

Mayo Clinic

Pain Physician | March 23, 2021 | Volume: 6;15 | Issue: 6;12 | Pages: 485-488

10.36076/ppj.2012/15/485 Get It

Background: Pain in the rectal, genital, and perineal area is a common condition treated by pain physicians. These chronic pain syndromes are therapeutically challenging because both interventional and drug therapies often are ineffective. Objectives: To determine if pelvic pain can be treated effectively with compounded topical amitriptyline-ketamine. Study Design: A retrospective review of medical records. Setting: A single academic medical center in the United States. Methods: We identified all patients treated with topical amitriptyline-ketamine from January 1, 2004, through November 28, 2011. Medical records were evaluated to determine the diagnosis for which the medication was prescribed. Treatment efficacy and any adverse effects were recorded. Results: Of the 1,068 patients who received amitriptyline-ketamine, 13 had the medication prescribed for genital, rectal, or perineal pain and had medication efficacy recorded. These patients were treated with a topical combination of amitriptyline 1-2% and ketamine 0.5%. Of these 13 patients, one (8%) had complete relief, 6 (46%) had substantial relief, 4 (31%) had some relief, and 2 (15%) had no response. One patient reported occasional irritation while using topical amitriptyline-ketamine with lidocaine; no other patients reported local or systemic adverse effects. Limitations: Retrospective review; lack of uniform system for pain grading; concurrent use of other medications. Conclusions: Topical amitriptyline-ketamine provided a high rate of pain relief with a low adverse-effect burden in patients with pelvic pain. This topical medication could offer an effective, noninvasive, nonopioid therapy for pain in the rectum, perineum, and genitals. Key words: Amitriptyline, rectal, compounded medication, genital, ketamine, pain, pelvic, perineal.
Superficial Granulomatous Pyoderma Gangrenosum Involving the Face: A Case Series of Five Patients and a Review of the Literature
Shavit, Eran , Limacher, James J. , Wentworth, Ashely, Davis, Mark D.P. , Alavi, Afsáneh , Davis, Mark Denis P., Alavi, A , Cecchini, Michael, Walsh, Scott R.

Mayo Clinic

Journal of Cutaneous Medicine and Surgery | February 9, 2021 | Volume: 25 | Issue: 4 | Pages: 371-376

10.1177/1203475420988864 | PMID 33541119 Get It

Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by painful and ulcerating lesions on the skin. It rarely involves the face and is often difficult to diagnose. There are few cases reported in the literature of PG involving the face. Aim To share our experience with 5 patients in whom the final diagnosis was PG involving the face, and to review the literature. Methods We report a series of 5 patients with a final diagnosis of PG involving the face and reviewed relevant literature. We searched through PubMed and EMBASE using keywords such as “face” and “pyoderma gangrenosum,” “blastomycosis-like pyoderma gangrenosum, vegetative pyoderma gangrenosum and granulomatous pyoderma gangrenosum.” Results We report 5 patients (4 females) with pyoderma gangrenosum involving the face. All 5 had a final diagnosis of superficial granulomatous PG. All cases presented with nonhealing facial ulcer most commonly on cheeks and a common histopathology of mixed inflammatory infiltrates, multinucleated giant cells, and plasma cells with some granulomatous inflammation. Conclusions PG can involve the face, and all 5 of our patients had the superficial granulomatous as the most common form.
Climate change perception among dermatologists: an online survey of International Society of Dermatology members
Andersen, Louise K. , Coates, Sarah J. , Enbiale, Wendemagegn , Boos, Markus D. , Dayrit, Johannes F. , Davis, Mark , Enbiale, Wendemagegne , Davis, Mark D. P.

Mayo Clinic

International Journal of Dermatology | June 12, 2020 | Volume: 59 | Issue: 9 | Pages: No page available

10.1111/ijd.14984 | PMID 32530127 Get It

Serum triamcinolone levels during intensive, inpatient wet‐dressing therapy
Mirza, Shireen, Wentworth, Ashley B., Harvey, Jamison A. , Bridges, Alina G. , Camilleri, Michael , McEvoy, M., Sartori‐Valinotti, Julio C. , Wetter, David A. , Davis, Mark D. P. , Sartori-Valinotti, J C , Mirza, S. A., el‐Azhary, Rokea A. , Davis, Mark D.P.

Mayo Clinic

Clinical and Experimental Dermatology | May 15, 2020 | Volume: 45 | Issue: 5 | Pages: 549-554

10.1111/ced.14161 | PMID 32410250 Get It

Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017
Roberts, Erin , Nowsheen, Somaira , Davis, Mark D. P. , McEvoy, M., Newman, Catherine C., Sartori‐Valinotti, Julio C. , Sciallis, Gabriel F., Torgerson, Rochelle R. , Wetter, David A. , Nowsheen, Somaira , Davis, Mark D.P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | February 20, 2020 | Volume: 34 | Issue: 9 | Pages: 2106-2110

10.1111/jdv.16302 | PMID 32078195 Get It

AbstractBackgroundFew large studies have assessed spironolactone treatment of adult female acne.ObjectivesTo explore the role of spironolactone in the treatment of adult female acne.MethodsWe performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017.ResultsIn total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two‐thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long‐term treatment with spironolactone (median duration, 13 months) and had few adverse effects.ConclusionsSpironolactone is a safe and effective treatment of acne for women.
The effects of climate change on human health in Africa, a dermatologic perspective: a report from the International Society of Dermatology Climate Change Committee
Coates, Sarah J. , Enbiale, Wendemagegn , Davis, Mark D.P., Andersen, Louise K. , Enbiale, Wendemagegne

Mayo Clinic

International Journal of Dermatology | January 23, 2020 | Volume: 59 | Issue: 3 | Pages: 265-278

10.1111/ijd.14759 | PMID 31970754 Get It

AbstractThroughout much of the African continent, healthcare systems are already strained in their efforts to meet the needs of a growing population using limited resources. Climate change threatens to undermine many of the public health gains that have been made in this region in the last several decades via multiple mechanisms, including malnutrition secondary to drought‐induced food insecurity, mass human displacement from newly uninhabitable areas, exacerbation of environmentally sensitive chronic diseases, and enhanced viability of pathogenic microbes and their vectors. We reviewed the literature describing the various direct and indirect effects of climate change on diseases with cutaneous manifestations in Africa. We included non‐communicable diseases such as malignancies (non‐melanoma skin cancers), inflammatory dermatoses (i.e. photosensitive dermatoses, atopic dermatitis), and trauma (skin injury), as well as communicable diseases and neglected tropical diseases. Physicians should be aware of the ways in which climate change threatens human health in low‐ and middle‐income countries in general, and particularly in countries throughout Africa, the world's lowest‐income and second most populous continent.
The Final Patch Test Read: Day 5 or Day >7?
Cantwell, Hafsa M. , Drage, Lisa A., Hall, Matthew R., Killian, Jill M. , Yiannias, James A. , Davis, Mark D.P. , el‐Azhary, Rokea A.

Mayo Clinic

Dermatitis® | January 8, 2020 | Volume: 31 | Issue: 1 | Pages: 42-52

10.1097/der.0000000000000562 | PMID 31913985 Get It

Background A major question in patch testing is when to perform the final reading. Our current standard practice is to place patches on day 1, remove them on day 3, and perform readings on days 3 and 5. For certain allergens, another reading is performed sometime from days 7 to 14≥. Objectives The aim of the study was to identify allergens with positive reactions on day 5 that were negative on day 7 or later and allergens with negative reactions on day 5 that were subsequently positive on day 7 or later. Methods We reviewed records of patients who underwent patch testing from January 2007 to December 2016 at Mayo Clinic with readings on day 5 and day 7 or later. Conclusions In total, 131 allergens had positive reactions on day 5 that were negative on day 7 or later, and 58 allergens had negative reactions on day 5 that were positive on day 7 or later. Twenty-five allergens had significantly higher reaction rates on day 5 than day 7 or later. Our standard practice is to perform readings on days 3 and 5 and on days 3, 5, and 7 or later for series containing metals. Readings on days 3, 5, and 7 or later should also be considered for acrylates.
Dubiously Doubtful: An Exploration of the Literature Concerning Doubtful, Macular Erythema, “?+,” and “+/−” Patch Test Reactions
Veverka, Kevin K. , Davis, Mark D. P. , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | January 5, 2020 | Volume: 31 | Issue: 1 | Pages: 36-41

10.1097/der.0000000000000533 | PMID 31905186 Get It

When the final patch test reading is barely discernable, it is termed a doubtful, macular erythema , “?+,” or “+/−” reaction (hereby referred to as doubtful reaction ). Information is conflicting about how to interpret doubtful reactions. Many guidelines do not comment on how to approach doubtful reactions; others state that further evaluation can (not should) be performed. In clinical reports, some investigators regard them as positive allergic reactions; some, as positive under certain circumstances; and many, as negative. Indeed, 16 (84%) of 19 recent reports of patch test reactions to standard/baseline series considered doubtful reactions negative for purposes of the report and did not include the number of these reactions. The problem is that these reactions are common and are not infrequently relevant. We recommend that researchers include frequency of doubtful reactions in reports and that doubtful reactions be assessed with the same scrutiny as stronger allergic reactions in the clinical setting.